Linoladiol (Estradiol Hemihydrate)

Estradiol Hemihydrate is employed in estrogen‑based hormone replacement therapy to address conditions related to low endogenous estrogen.

• Vaginal atrophy: improves dryness, irritation and dyspareunia.
• Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats.
• Hypoestrogenism due to ovarian failure: restores systemic estrogen activity and supports bone health.

• Estradiol Hemihydrate binds to intracellular estrogen receptors (ERα and ERβ) in target tissues, forming a hormone‑receptor complex that interacts with estrogen response elements on DNA. This modulates transcription of genes involved in cellular growth, differentiation, and maintenance of reproductive and skeletal tissues, producing the characteristic estrogenic effects.

Estradiol Hemihydrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Vaginal irritation or discharge
• Headache
• Breast tenderness
• Nausea or abdominal bloating
• Mood changes
• Mild skin rash

Serious or Rare Side Effects

• Thromboembolic events (deep vein thrombosis, pulmonary embolism)
• Stroke or transient ischemic attack
• Myocardial infarction
• Endometrial hyperplasia or carcinoma
• Severe allergic reaction (anaphylaxis)
• Liver function abnormalities

When prescribing Estradiol Hemihydrate, clinicians should consider patient‑specific risk factors and monitor for adverse events.

• History of thromboembolism: avoid or use with caution.
• Cardiovascular disease: assess risk before initiating therapy.
• Liver impairment: adjust dosage or consider alternative therapy.
• Undiagnosed vaginal bleeding: evaluate before use.
• Pregnancy or breastfeeding: contraindicated unless benefits outweigh risks.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Estradiol Hemihydrate can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Aromatase inhibitors: antagonistic effect reducing estrogen activity.
• Tamoxifen: competitive antagonism at estrogen receptors.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol plasma levels.
• Antihypertensives: potential alteration of blood pressure control.
• Lithium: may increase risk of breast tenderness and edema.